Le laboratoire américain Pfizer est revenu sur le devant de la scène, hissé par le succès de son vaccin contre le Covid-19. Une réussite qui ne doit rien au hasard.

Infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provides immunity against seasonal human coronaviruses (HCoVs). Whether SARS-CoV-2 infection causes a boost in the preexisting HCoV-specific antibodies or elicits cross-reactive β-CoV antibodies that target conserved epitopes is unknown.

The startup helps people suffering from chronic illnesses by selling its remote-monitoring and gamified healthcare platform to major pharmaceutical companies like Pfizer and Bayer and private insurers in the US and Europe. Sidekick is developing 18 digital treatments, covering conditions as diverse as diabetes and ulcerative colitis, and has 14 of those out in commercial partnerships. Eventually, Thorgeirsson tells Sifted, the plan is to build out more than 40 digital therapies. The idea is to provide ultra-personalised app-based treatment that can manage illness and catch serious conditions before they become life threatening, he adds.

In a recent study posted to the medRxiv* preprint server, researchers assessed the induction of variant-specific neutralizing antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) and nucleocapsid (N) proteins of several SARS-CoV-2 strains.

Chimeric antigen receptor T-cell therapy, or CAR T, has made a big impact on the treatment of certain blood cancers, allowing patients with relapsed/refractory disease to live longer, healthier lives. But in clinical study, the cellular therapy has not been as successful for patients with solid tumors, due in part to the lack of tumor targets not expressed in vital tissues. In a new study published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, Moffitt Cancer Center researchers share the identification of a new potential target for CAR T cells called OR2H1 that they have demonstrated inhibits growth in lung and ovarian tumors.

A group of researchers led by St. Michael's Hospital of Unity Health Toronto recruited a total of 786 patients across nine primary care sites in Ontario who reported cost-related non-adherence to medications. Most of the study participants were recruited from St. Michael's Department of Family and Community Medicine and others were recruited from three rural sites. Participants were randomized into two groups - half received free medications via mail, the other half had their usual access to medications.

The success of chimeric antigen receptor (CAR) T cell therapy in solid tumors, unlike in hematologic malignancies, is limited by inadequate tumor infiltration and T cell dysfunction and exhaustion. Regional delivery of CAR T cells in patients with solid tumors is safe and feasible; promotes infiltration, proliferation, and trafficking; and ignites functionally persisting systemic immunity.

Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary.

The reality is that walking 10,000 steps a day is a laudable goal and is almost certainly beneficial. But even lower levels of physical activity have benefits. The trick is not so much to aim for some theoretical ideal but to improve upon your current baseline. Encouraging patients to get into the habit of taking a daily walk (be it in the morning, during lunchtime, or in the evening) is going to pay dividends regardless of their daily step count. The point is that when it comes to physical activity, the greatest benefit seems to be when we go from doing nothing to doing something.

A new technique uses ultrasound waves to mechanically eliminate up to 75 percent of cancer cells, freeing the immune system to fight off the rest, and more.

C’est l’université allemande de Heidelberg qui a mené cette étude pour le moins originale. Les chirurgiens étaient soumis à différents niveaux sonores avec soit la musique des Beatles soit au hard rock d'AC/DC, tandis que leurs gestes étaient analysés de près, sur base de la vitesse et la précision de leurs coupes chirurgicales.

VR-based interventions were found to improve psychological and physical symptoms in the breast cancer setting; however, there was little evidence to support VR-based interventions for improving fatigue. Additional large-scale pilot studies are needed to validate these findings.

Versant Ventures has launched Cimeio Therapeutics, a biotech startup with technology that can shield transplanted stem cells or cell therapies. Shielding these cells enables them to be dosed alongside an immunotherapy—an approach that is not currently done because the therapies don’t discriminate between diseased cells and transplanted ones.

ROCHESTER, Minn. — Researchers at Mayo Clinic's Center for Individualized Medicine have devised an immunotherapy technique that combines chimeric antigen receptor-T cell therapy, or CAR-T cell therapy, with a cancer-killing virus to more effectively target and treat solid cancer tumors.  The combination approach, published in Science Translational Medicine, involves loading CAR-T cells, which are engineered […]

Des échantillons d'eau de mer collectés dans le monde entier ont permis d'identifier plus de 5 000 nouvelles espèces de virus à ARN. Ces travaux élargissent les possibilités de recherche écologique et remodèlent notre compréhension

Ronawk has developed a new 3D solution that enables easy growth of large quantities of cells of a consistent phenotype. The company’s CEO and Founder A.J. Mellott, Ph.D. and Chief Revenue Officer Scott Leigh discuss the potential applications for the technology and their hopes for enabling significant advances in pharma manufacturing and beyond with Pharma’s Almanac Editor in Chief David Alvaro, Ph.D.

Obesity is a disease, and America’s healthcare providers and hospital systems must be part of changing how we treat it. That means many of us in the health ecosystem must reexamine how we view patients with excess weight.

If you’re worried about lung cancer, then smoking is incredibly dangerous. The chance of a non-smoker developing the disease is roughly one in 6,000. For someone who smokes regularly, the chances skyrocket to one in five or ten. And yet, most people who smoke won’t develop lung cancer.

Models continue to evolve to guide innovators along the commercialization path. The probability of commercial success is maximized by different commercialization strategies depending on ovation is in the diffusion process and the type of innovation. where the innovation is in the diffusion process and the type of innovation.

A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data from a phase I/II clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.